Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

8.17HKD
30 Oct 2020
Change (% chg)

HK$-0.27 (-3.20%)
Prev Close
HK$8.44
Open
HK$8.35
Day's High
HK$8.44
Day's Low
HK$8.04
Volume
75,294,558
Avg. Vol
59,413,928
52-wk High
HK$11.35
52-wk Low
HK$6.83

Latest Key Developments (Source: Significant Developments)

CSPC Pharmaceutical Says 9-Mth Revenue For CSPC Innovation Pharmaceutical RMB1.03 Bln
Thursday, 22 Oct 2020 

Oct 22 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::9-MONTH REVENUE FOR CSPC INNOVATION PHARMACEUTICAL RMB1.03 BILLION, UP 7.58%.9-MONTH NET PROFIT ATTRIBUTABLE FOR CSPC INNOVATION PHARMACEUTICAL RMB 257.2 MILLION, UP 20.56%.  Full Article

CSPC Pharmaceutical Says "Docetaxel For Injection (Albumin-Bound)" Gets Clinical Trial Approval In U.S
Thursday, 17 Sep 2020 

Sept 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::"DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN U.S.  Full Article

Cspc Pharmaceutical Says Almb-0168 Obtains Clinical Trial Approval For Investigational New Drug In China
Tuesday, 15 Sep 2020 

Sept 15 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::ALMB-0168 OBTAINS CLINICAL TRIAL APPROVAL FOR NVESTIGATIONAL NEW DRUG IN CHINA.  Full Article

CSPC Pharmaceutical HY Profit Attributable RMB2.31 Bln
Wednesday, 26 Aug 2020 

Aug 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::HY PROFIT ATTRIBUTABLE RMB2.31 BILLION VERSUS RMB1.88 BILLION.HY TOTAL REVENUE RMB12.59 BILLION VERSUS RMB11.18 BILLION.INTERIM DIVIDEND PER SHARE HK6 CENTS.  Full Article

CSPC Pharmaceutical Announces Acceptance Of NDA
Tuesday, 25 Aug 2020 

Aug 25 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::NDA FOR UNIT'S MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION ACCEPTED BY CENTER FOR DRUG EVALUATION OF NMPA.  Full Article

CSPC Pharmaceutical Says Unit's "Syha1815 Tablets" Obtained Approval By NMPA
Monday, 24 Aug 2020 

Aug 24 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT'S "SYHA1815 TABLETS" OBTAINED APPROVAL BY NMPA TO CONDUCT CLINICAL TRIALS IN CHINA.  Full Article

Cspc Pharmaceutical Posts HY Net Profit Attributable Of CSPC Innovation Pharma RMB 179.5 MLN
Thursday, 20 Aug 2020 

Aug 20 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::HY NET PROFIT ATTRIBUTABLE OF CSPC INNOVATION PHARMACEUTICAL CO RMB 179.5 MILLION VERSUS RMB 137 MILLION.CSPC INNOVATION PHARMACEUTICAL'S HY REVENUE RMB687.2 MILLION VERSUS RMB653.5 MILLION.  Full Article

Cspc Pharmaceutical Says Unit's Memantine Hydrochloride Tablets (5Mg, 10Mg) Obtained Drug Registration By NMPA
Tuesday, 21 Jul 2020 

July 21 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT'S MEMANTINE HYDROCHLORIDE TABLETS (5MG, 10MG) OBTAINED DRUG REGISTRATION BY NMPA.  Full Article

Cspc Pharmaceutical Says Bortezomib For Injection Obtains Drug Registration Approval By Npma Of PRC
Tuesday, 23 Jun 2020 

June 23 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL - BORTEZOMIB FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL BY NPMA OF PRC.  Full Article

CSPC Pharmaceutical Says Co's Drug Obtained Approval From National Medical Products Administration To Conduct Clinical Trials In China
Thursday, 28 May 2020 

May 28 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CO'S DRUG OBTAINED APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION TO CONDUCT CLINICAL TRIALS IN CHINA.  Full Article

Alibaba Health raises $1.3 billion in HK's biggest secondary share sale in 5 years

HONG KONG Alibaba Health Information Technology has raised nearly $1.3 billion in Hong Kong's largest follow-on share sale since 2015, and industry experts say this could prompt more firms to tap investors for cash in the Asian financial hub.